Abeona Therapeutics

Abeona Therapeutics is a clinical stage company developing gene therapy and plasma-based therapies for severe and life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Company Growth (employees)
Type
Public
HQ
Dallas, US
Founded
2013
Size (employees)
19 (est)+217%
Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Abeona Therapeutics Office Locations

Abeona Therapeutics has an office in Dallas
Dallas, US (HQ)
600 3333 Lee Pkwy
Show all (1)

Abeona Therapeutics Financials and Metrics

Abeona Therapeutics Financials

Abeona Therapeutics's revenue was reported to be $889 k in FY, 2016
USD

Revenue (Q3, 2017)

219 k

Net income (Q3, 2017)

(5.3 m)

EBIT (Q3, 2017)

(5.4 m)

Market capitalization (22-Dec-2017)

13.7 m

Cash (30-Sep-2017)

56.5 m
Abeona Therapeutics's current market capitalization is $13.7 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2 m925 k1 m889 k

Revenue growth, %

(55%)12%(15%)

R&D expense

10.7 m

General and administrative expense

13.3 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

189 k208 k247 k236 k258 k285 k235 k214 k184 k186 k217 k219 k

R&D expense

236 k72 k81 k73 k453 k1.6 m1.9 m3 m2.7 m2.2 m5.8 m3.3 m

General and administrative expense

642 k733 k868 k795 k1.7 m4.7 m4.4 m3.7 m2.4 m3 m2.6 m2.2 m

Operating expense total

885 k805 k950 k869 k2.3 m6.4 m6.4 m6.9 m5.4 m5.5 m8.7 m5.6 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

424 k11.5 m40.1 m69.1 m

Inventories

77 k315 k155 k

Current Assets

575 k11.6 m40.6 m69.4 m

PP&E

6 k4 k350 k721 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

899 k299 k55 k165 k7.9 m43.3 m37.4 m34.3 m31.2 m63.2 m58.3 m56.5 m

Inventories

1.8 m

Current Assets

1 m440 k203 k244 k8.2 m43.7 m37.8 m34.6 m31.9 m63.8 m59.3 m58.4 m

PP&E

6 k6 k5 k4 k11 k87 k548 k639 k748 k748 k709 k730 k
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    4.4 m(26.8 m)(14.5 m)(21.9 m)

    Depreciation and Amortization

    3 k11 k551 k825 k

    Inventories

    174 k77 k(287 k)160 k

    Accounts Payable

    (1.2 m)33 k(1.2 m)2.8 m
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    (157 k)(128 k)(12.5 m)(1.5 m)(2 m)(12.2 m)(5.5 m)(12.2 m)(14.9 m)(5.2 m)

    Depreciation and Amortization

    1 k1 k118 k401 k174 k355 k577 k250 k

    Accounts Payable

    1.1 m1.3 m1.6 m638 k(1.1 m)1 m1.2 m1 m1.5 m

    Cash From Operating Activities

    (7.5 m)(5.6 m)(9.6 m)
      Y, 2017

      Financial Leverage

      1.1 x
      Show all financial metrics

      Abeona Therapeutics Market Value History

      Abeona Therapeutics's Web-traffic and Trends

      Abeona Therapeutics Online and Social Media Presence

      Abeona Therapeutics Company Life and Culture

      You may also be interested in